Abstract:Bowen Wei, 1, 2, &ast Qingyun Yue, 1, 2, &ast Yuxiu Ka, 1, 2, &ast Chenyang Sun, 1, 2 Yuxing Zhao, 1, 2 Xiaomei Ning, 1, 2 Yue Jin, 1, 2 Jingyue Gao, 1, 2 Yuanhao Wu, 1, 2 Wei Liu 1, 2 1 Department of Rheumatism and Immunity, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China; 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Liu, Email Background: Primary Sjögren's syndrome (pSS) is an autoimmune condition marked by lymphocyte infiltration in the exocrine glands. Our study aimed to identify a novel biomarker for pSS to improve its diagnosis and treatment. Methods: The gene expression profiles of pSS were obtained from the Gene Expression Omnibus (GEO) database. The specific differentially expressed genes (DEGs) were screened by the Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Recursive Feature Elimination with Support Vector Machines (SVM-RFE). A biomarker was picked out based on correlation and diagnostic performance, the connection between the biomarker and clinical traits and immune infiltrating cells was explored, and the biomarker's protein expression level in the serum of pSS patients was detected by enzyme-linked immunosorbent assay (ELISA). The competitive endogenous RNA (ceRNA) network regulated by the biomarker was predicted to verify the reliability of the biomarker in diagnosing pSS. Results: IFI44, XAF1, GBP1, EIF2AK2, IFI27 , and IFI6 showed prominent diagnostic ability, with the high accuracy (AUC = 0.859) and significance (R ≥ 0.8) of IFI44 within the training dataset. IFI44 strongly exhibited a negative correlation with resting NK cells, macrophages M0, and eosinophils, and a positive correlation with activated dendritic cells, naive B cells, and activated CD4 memory T cells. Furthermore, IFI44 was significantly positively correlated with clinical traits such as IgG, SSA, SSB, ANA, and ESSDAI, with its protein expression level in the serum of pSS patients being notably elevated compared to controls ( p < 0.001). Finally, the ceRNA regulatory network showed that hsa-miR-944, hsa-miR-9-5p, hsa-miR-126-5p, and hsa-miR-335-3p were significantly targeted IFI44 , suggesting that IFI44 may serve as a dependable biomarker for pSS. Conclusion: In this study, we dug out IFI44 as a biomarker for pSS, systematically studied the potential regulatory mechanism of IFI44 , and verified its reliability as a biomarker for pSS. Keywords: primary Sjögren's syndrome, machine learning, immune cell infiltration, biomarker, IFI44 Primary Sjögren's syndrome (pSS) is a complicated and heterogeneous autoimmune disorder with clinical symptoms characterized by exocrine gland dysfunction 1 and immunopathogenesis involving infiltration of T and B lymphocytes, 2 which will lead to symptoms such as xerostomia, xerophthalmia, fatigue, joint pain, and potentially resulting in serious complications such as lymphoma. 3 The prevalence of pSS ranges from 0.03% to 5% across different countries, while, it is about 0.33–0.77% in China, 4,5 and the standard death rate is 3.63. 6 However, the precise biological mechanisms underlying pSS remain unclear, with no definitive diagnostic markers that are both sensitive and specific. Understanding the pathophysiology linked to pSS is essential for diagnosing and treating patients experiencing dryness symptoms, fatigue, and joint discomfort, thereby enhancing their quality of life. Because of the clinical heterogeneity of pSS, the current diagnostic method relies on minor salivary gland biopsy (MSGB) 7,8 in conjunction with clinical symptoms and autoimmune serology. 9,10 Typical diagnostic markers for pSS include anti-Ro/SSA, anti-La/SSB, antinuclear antibodies, rheumatoid factor, etc. 11,12 However, MSGB, an invasive test, may lead to uncomfortable symptoms and complicating disease 13 and the diagnosis may be influenced by the subjective decision of the observer. 14 Anti-Ro/SSA antibodies may suggest a more advanced disease stage, and depending solely on it for diagnosis may result in insufficient detection of early pSS. 15 Furthermore, patients with primary biliary cholangitis (formerly cal -Abstract Truncated-

A novel enzyme-linked immunosorbent assay tool to evaluate plasma soluble CD226 in primary Sjögren's syndrome

Biomarkers for Primary Sjögren’s Syndrome

Development of a Sandwich ELISA for Evaluating Soluble PD-L1 (CD274) in Human Sera of Different Ages As Well As Supernatants of PD-L1+ Cell Lines

Evaluation Of Soluble Cd25 As A Clinical And Autoimmune Biomarker In Primary Sjogren'S Syndrome

Investigation of Three Potential Autoantibodies in Sjogren's Syndrome and Associated MALT Lymphoma

Increased CD200 Levels in Peripheral Blood Mononuclear Cells of Patients with Primary Sjögren's Syndrome.

Identification and Verification of Inflammatory Biomarkers for Primary Sjögren’s Syndrome

Non-invasive diagnosis of primary Sjögren's syndrome using ultrasonography and transcriptome biomarkers

Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren's Syndrome

Integrated Bioinformatics and Validation Reveal Potential Biomarkers Associated With Progression of Primary Sjögren's Syndrome

Epithelial Cell Adhesion Molecule in Primary Sjögren’s Syndrome Patients: Characterization and Evaluation of a Potential Biomarker

Immunoassay Detects Salivary Anti-SSA/Ro-52 Autoantibodies in Seronegative Patients with Primary Sjögren's Syndrome.

Tissue-Specific Autoantibodies Improve Diagnosis of Primary Sjögren’s Syndrome in the Early Stage and Indicate Localized Salivary Injury

Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome

Proteomics of saliva, plasma, and salivary gland tissue in Sjögren's syndrome and non-Sjögren patients identify novel biomarker candidates

The role of imbalanced CD226/TIGIT on activated peripheral double-negative T cells in the pathogenesis of primary Sjögren's syndrome

Serum IgA Against Type 3 Muscarinic Acetylcholine Receptor is a Novel Marker in Diagnosis of Sjögren's Syndrome.

Identification of inflammatory markers as indicators for disease progression in primary Sjögren syndrome

Serum biomarker-based risk model construction for primary Sjögren's syndrome with interstitial lung disease

Shared biomarkers of multi-tissue origin for primary Sjogren's syndrome and their importance in immune microenvironment alterations

Novel autoantibodies help diagnose anti-SSA antibody negative Sjögren disease and predict abnormal labial salivary gland pathology